We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
12 own
24 watching
Current Price
$0.44
$-0.01
(-2.06%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
26.87M
52-Week High
4.83
52-Week Low
0.372
Average Volume
1.06M
Dividend Yield
--
P/E Ratio
--
Market Capitalization26.87M
52-Week High4.83
52-Week Low0.372
Average Volume1.06M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company s lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Zolmax
22days ago
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE Get Rating) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 611,000 shares, an increase of 17.8% from the October 15th total of 518,700 shares. Based on an average daily trading ...
Ticker Report
1month ago
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE Get Rating) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 518,700 shares, a decline of 24.1% from the September 30th total of 683,100 shares. Based on an average ...
PR Newswire
3 months ago
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring PR Newswire AUSTIN, Texas, Aug. 24, 2022 PrioritizingResources and Focus on AGLE-177 and the Completion of the Ongoing Phase 1/2...
PR Newswire
3 months ago
Thinking about buying stock in Volcon, Aeglea Bio Therapeutics, StoneCo, Party City, or FuelCell Energy? Thinking about buying stock in Volcon, Aeglea Bio Therapeutics, StoneCo, Party City, or FuelCell Energy? PR Newswire NEW YORK, Aug. 19, 2022 NEW YORK, Aug. 19, 2022 /PRNewswire...
Ticker Report
5 months ago
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE Get Rating) insider Jr. Michael Conick Hanley bought 28,200 shares of the companys stock in a transaction on Wednesday, June 8th. The stock was bought at an average price of $0.71 per share, for a total transaction of $20,022.00. Following the...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0.44
$-0.01
(-2.06%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00